Status:
COMPLETED
Clinical Utility Trial for the SomaLogic CVD-T2D Test
Lead Sponsor:
Qure Healthcare, LLC
Collaborating Sponsors:
SomaLogic, Inc.
Conditions:
Cardiovascular Diseases
Type 2 Diabetes
Eligibility:
All Genders
Phase:
NA
Brief Summary
QURE will use its CPV technology in a randomized controlled trial to measure how SomaLogic's diagnostic test (the Cardiovascular Disease in Type 2 Diabetes) changes clinical practice and improves pati...
Detailed Description
SomaLogic has developed a pioneering technology, the SomaScan® Platform, the first and only platform, that simultaneously measures 7,000 proteins. The company's technology is based on proprietary apta...
Eligibility Criteria
Inclusion
- Board-certified primary care physicians or cardiologist for at least two years
- Averaging at least 20 hours per week of clinical and patient care duties over the last six months
- Routinely evaluate patients with diabetes mellitus in their practice
- Practicing in the U.S.
- English speaking
- Access to the internet
- Informed, signed and voluntarily consented to be in the study
Exclusion
- Non-English speaking
- Practicing in an academic setting
- Unable to access the internet
- Not practicing in the U.S.
- Not averaging at least 20 hours per week of clinical or patient care duties over the last six months
- Previous exposure to the CVD-T2D test
- Do not voluntarily consent to be in the study
Key Trial Info
Start Date :
March 15 2022
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
August 15 2022
Estimated Enrollment :
251 Patients enrolled
Trial Details
Trial ID
NCT05237271
Start Date
March 15 2022
End Date
August 15 2022
Last Update
August 22 2022
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
QURE Healthcare
San Francisco, California, United States, 94133